Log in

Forgot password

Not a member?

Register now

All-cause pressure ulcer (PU) inpatient readmissions or outpatient revisits with SANTYL Ointment + standard of care (SOC) vs medicinal honey + SOC

  • Patients treated with SANTYL Ointment returned to the inpatient and outpatient hospital setting less often compared with those treated with medicinal honey23
  • These results from real-world administrative data help gain an understanding of the economic implications of debridement choice in the acute care setting.23
  • Comparisons were made between both groups at 30-, 60-, 90-, and 180-days post inpatient or outpatient index visit23

Hospital outpatient re-encounters at 180 days

8%

lower with SANTYL Ointment + SOC in both hospital inpatient* and outpatient settings

vs medicinal honey + SOC23

n=46,054

* Outpatient re-encounter rate at 180 days after inpatient index visit was 26% for the SANTYL Ointment group vs 34% for the medicinal honey group (P<0.05).

Outpatient re-encounter rate at 180 days after outpatient index visit was 63% for the SANTYL group vs 71% for the medicinal honey group (P<0.05).

Study details

Study overview, endpoints, and design

Dreyfus J, et al. (2018)23
Objective Determine the proportion of PU patients treated with SANTYL Ointment or medicinal honey among inpatients and outpatients in US hospitals, and then compare hospital utilization post-discharge for both debridement methods.
Primary endpoint Determine all-cause inpatient readmissions or outpatient revisits to the same hospital at 30, 60, 90, and 180 days post-index discharge date.
Limitations
  • Study was observational in nature
  • Possible selection bias: No adjustment made for initial hospitalization cause or reason for return
Patient demographics

Inpatients§ with PUs treated with:

  • SANTYL Ointment (n=44,725)
    • Gender: 49.4% male, 50.6% female
    • Mean age: 71.1 years
    • Race: 61.7% white, 23.4% black, 14.9% other
  • Medicinal honey: (n=3,542)
    • Gender: 48.6% male, 51.4% female
    • Mean age: 71.0 years
    • Race: 75.9% white, 12.7% black, 11.4% other

Outpatients|| with PUs treated with:

  • SANTYL Ointment (n=1,826)
    • Gender: 46.8% male, 53.2% female
    • Mean age: 70.0 years
    • Race: 68.1% white, 15.0% black, 16.9% other
  • Medicinal honey (n=773)
    • Gender: 53.3% male, 46.7% female
    • Mean age: 66.3 years
    • Race: 77.9% white, 15.0% black, 7.1% other
Data source

US Premier Healthcare Database: Extracted hospital discharge records for patients receiving debridement and having an ICD-9 code for PU.

Two arms:

  • SANTYL Ointment + SOC
  • Medicinal honey + SOC

>77% of inpatients and >74% of outpatients had Medicare health coverage. >9% of inpatients and >10% of outpatients had commercial insurance.

§ There was no significant difference in comorbidities (immobility, neuropathy, urinary incontinence, chronic kidney disease, or diabetes) between the SANTYL Ointment and medicinal honey cohorts.

|| There was no significant difference in comorbidities (immobility, neuropathy, heart failure) between the SANTYL Ointment and medicinal honey cohorts, however, the SANTYL Ointment cohort had more malnutrition, urinary incontinence, chronic kidney disease, dementia, and diabetes.

Database complies with the Health Insurance Portability and Accountability Act of 1996.

Study results

SANTYL Ointment demonstrated fewer outpatient re-encounters vs medicinal honey

  • The medicinal honey group had a higher frequency of 180-day readmissions, as well as outpatient re-encounters at 30-, 60-, 90-, and 180-day follow-up after inpatient index visits
  • After outpatient index visits, there were no statistically significant differences in inpatient revisits, but a higher proportion of the medicinal honey group had outpatient revisits at all follow-up time points
  • Adjusted odds ratios odds for outpatient revisits after inpatient and outpatient index visits were greater for the medicinal honey-treated group at 30, 60, 90, and 180 days

Log in or register to download clinical study: Hospital inpatient/outpatient re-encounters with SANTYL Ointment vs medicinal honey

What's next?

Economic study: Cost-effectiveness of SANTYL Ointment vs medicinal honey in HOPD setting

Important Safety Information:Use of SANTYL Ointment should be terminated when debridement is complete and granulation tissue is well established.

One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone. Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound.